On Raltitrexed dual pathways in combination with cisplatin in elderly patients with advanced clinical effects of chemotherapy in the treatment of colorectal cancer
To investigate in elderly patients with advanced colorectal cancer in combination with raltitrexed and cisplatin double chemotherapy clinical efficacy and safety. Methods: 2011 ~ 2013 in our hospital 48 cases of elderly patients with advanced colorectal cancer patients were randomly grouped, 24 cases in each group, which wil be implemented raltitrexed and cisplatin infusion chemotherapy classified as the control group wil be implemented Raltitrexed intravenous chemotherapy with cisplatin intraperitoneal treatment group classified as observation, comparison and evaluation of clinical outcomes between the two groups, including both short-term efficacy, safety, and so on. Results: After treatment available to 58.3%of short-term efficacy (including CR 3 例 , PR 11 cases), compared with 20.8% in the control group even better, more significant differences (P <0.05). In terms of security, the observation group, 9 patients (37.5%) discomfort, and 45.8% in the control group relative ratio slightly better, but no significant difference (P> 0.05). Conclusion: providing elderly patients with advanced colorectal cancer patients Raltitrexed intravenous chemotherapy and intraperitoneal cisplatin therapy of two ways, able to achieve more desirable clinical efficacy and safety of relatively reliable, suitable for universal application in future clinical .
raltitrexedcisplatinelderly, advanced colorectal cancer
NETL
NSTL
万方数据
